Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.53 |
| ▸ | GSK3B | P49841 | 9/20 | 0.53 |
| ▸ | WNT1 | P04628 | 5/20 | 0.53 |
| ▸ | CLK2 | P49760 | 2/20 | 0.52 |
| ▸ | CLK3 | P49761 | 2/20 | 0.52 |
| ▸ | MET | P08581 | 2/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | LIPC | P11150 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19611107 | 0.85 | DYRK1A (0.54) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL15508164 | 0.83 | TTK (0.61) | TTKMETTNK2LIPCFGFR1 | |
| SCHEMBL30132241 | 0.83 | TTK (0.61) | TTKMETTNK2LIPCFGFR1 | |
| SCHEMBL320089 | 0.83 | CCNC (0.51) | TTKMETTNK2GPR119LIPC | |
| SCHEMBL19611106 | 0.82 | DYRK1A (0.52) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL18318621 | 0.81 | CHEK2 (0.52) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL15884624 | 0.81 | MET (0.58) | TTKMETTNK2GPR119LIPC | |
| SCHEMBL20945239 | 0.81 | DYRK1A (0.80) | TTKDYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL20135336 | 0.80 | GPR119 (0.58) | TTKMETTNK2GPR119LIPC | |
| SCHEMBL2749132 | 0.80 | MET (0.53) | TTKDYRK1AGSK3BWNT1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188642-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-10188642-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9895364-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-9895364-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-9895364-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| EP-2892890-B1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-11-22 | — | — | EP | disclosed |
| US-20160296514-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-10-13 | — | — | US | disclosed |
| US-20160296514-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-10-13 | — | — | US | disclosed |
| US-20160296514-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2016-10-13 | — | — | US | disclosed |
| US-9334286-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-9334286-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-9334286-B2 | Pharmacologically active compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218181-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | BUB1B, BUB1, PLK1 | TTK 26/4885DYRK1A 1250/4885GSK3B 271/4885 |
| US-20180117032-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | BUB1B, BUB1, PLK1 | TTK 26/4885DYRK1A 1250/4885GSK3B 271/4885 |
| US-10188642-B2 | Pharmacologically active compounds | BUB1B, BUB1, PLK1 | TTK 26/4885DYRK1A 1250/4885GSK3B 271/4885 |
| US-20160296514-A1 | PHARMACOLOGICALLY ACTIVE COMPOUNDS | BUB1B, BUB1, PLK1 | TTK 26/4885DYRK1A 1250/4885GSK3B 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.